Allena Pharmaceuticals : ALLN-346 for the Treatment of Gout in Chronic Kidney Disease

ALLN-346 for the Treatment of Gout in Chronic Kidney Disease

KOL webinar hosted by Allena Pharmaceuticals, Inc. (Nasdaq: ALNA)

June 16, 2021 12:00 pm ET

Allena Pharmaceuticals, Inc.

These slides, and the accompanying presentation, contain forward-looking statements and information. The use of words such as "may," "might," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "project," "intend," "future," "potential," or "continue," and other similar expressions are intended to identify forward-looking statements. All forward-looking statements are based on estimates and assumptions by our management that, although we believe them to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that we expected, including those risks and uncertainties that are described under the heading "Risk Factors" in our Quarterly Report on Form 10-Q for the three months ended March 31, 2021, as well as discussions of potential risks, uncertainties and other important factors in our subsequent filings with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

This presentation also contains estimates and other statistical data made by independent parties and us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.

2

Agenda

• Welcome and Opening Remarks - Louis Brenner, M.D., President and Chief Executive Officer
• Key Opinion Leader - Robert Terkeltaub, M.D., Professor of Medicine, University of California San Diego
• Market Overview - Geoffrey Swire, Senior Vice President, Corporate Development
• ALLN-346Development Program - David J. Clark, M.D., Chief Medical Officer
• Q&A - All speakers
• Closing remarks - Louis Brenner, M.D., President and Chief Executive Officer

3

Leadership in Oral Enzyme Technology for Metabolic and Kidney Disorders

Formulation	Oral	Non-	GI Mechanism
Technology	Enzymes	Absorbed	of Action

Reloxaliase

ALLN-346

Enhanced stability	Therapeutic	Reduces	Leverage
in the GI tract and	candidates that	potential for	GI tract as
proprietary CMC	degrade a specific	adverse events	"auxiliary kidney"
approach	metabolite

Technology platform encompasses broad set of core competencies

4

First-in-Class Oral Biologics

Product	Indication	Discovery Preclinical Phase 1	Phase 2	Phase 3	Next Milestone	Timing
Reloxaliase	Enteric Hyperoxaluria				URIROX-2 Interim	2Q/3Q- 2022
			Analysis
	Hyperuricemia and				Phase 1b MAD Data	Q3 - 2021
ALLN-346	Gout with Chronic				Initial Phase 2a
	Kidney Disease
				Program Data	Q4 - 2021
Oral Enzyme	Metabolic Disease				Initiation of new	H2 - 2021
Candidate(s)				program

Allena has retained worldwide rights for all programs

5